{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T06:39:38Z","timestamp":1648881578072},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.ygyno.2005.07.114","type":"journal-article","created":{"date-parts":[[2005,9,9]],"date-time":"2005-09-09T15:51:53Z","timestamp":1126281113000},"page":"111-115","source":"Crossref","is-referenced-by-count":3,"title":["A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"100","author":[{"given":"M. Dwight","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gini F.","family":"Fleming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suann","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ira","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2005.07.114_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA J. Cancer Clin."},{"key":"10.1016\/j.ygyno.2005.07.114_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2005.07.114_bib3","first-page":"789","article-title":"Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin","volume":"46","author":"Gallo","year":"1971","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2005.07.114_bib4","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.1992.10.4.647","article-title":"Phase I and pharmacologic study of topotecan (SK and F 104864): a novel topoisomerase inhibitor","volume":"10","author":"Rowinsky","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.114_bib5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev.pa.34.040194.001203","article-title":"DNA topoisomerases: essential enzymes and lethal targets","volume":"34","author":"Chen","year":"1994","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ygyno.2005.07.114_bib6","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.114_bib7","article-title":"Antiviral activity of 2\u2032, 2\u2032 difluorodeoxycitidine","author":"DeLong","year":"1995"},{"issue":"Suppl 11","key":"10.1016\/j.ygyno.2005.07.114_bib8","first-page":"19","article-title":"Induction of apoptosis by gemcitabine","volume":"22","author":"Huang","year":"1995","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.114_bib9","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2\u2032,2\u2032-difluoro-2\u2032deoxycytidine)","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.114_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/gyno.1996.0284","article-title":"Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel","volume":"63","author":"Shapiro","year":"1996","journal-title":"Gynecol. Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.ygyno.2005.07.114_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/00001813-199512006-00010","article-title":"Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients","volume":"6","author":"Lund","year":"1995","journal-title":"Anticancer Drugs"},{"issue":"Suppl 10","key":"10.1016\/j.ygyno.2005.07.114_bib12","first-page":"32","article-title":"Gemcitabine safety overview","volume":"23","author":"Green","year":"1996","journal-title":"Semin Oncol."},{"key":"10.1016\/j.ygyno.2005.07.114_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.1997.15.1.44","article-title":"Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia","volume":"15","author":"Seiter","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2005.07.114_bib14","first-page":"2499","article-title":"Gemcitabine (2\u2032,2\u2032-difluoro-2\u2032-deoxycytidine), an antimetabolite that poisons topoisomerase I","volume":"8","author":"Pourquier","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2005.07.114_bib15","first-page":"355","article-title":"Antagonistic effect of the combination gemcitabine\/topotecan in ovarian cancer cells","volume":"12","author":"Distefano","year":"2000","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ygyno.2005.07.114_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000055291","article-title":"Topotecan and gemcitabine in platinum\/paclitaxel-resistant ovarian cancer","volume":"60","author":"Greggi","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.ygyno.2005.07.114_bib17","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1081\/CNV-100103845","article-title":"A phase I\u2013II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3)","volume":"19","author":"Rinaldi","year":"2001","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ygyno.2005.07.114_bib18","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/1097-0142(20010715)92:2<414::AID-CNCR1337>3.0.CO;2-W","article-title":"A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors","volume":"92","author":"Sun","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2005.07.114_bib19","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1634\/theoncologist.7-6-509","article-title":"A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer","volume":"7","author":"Guarino","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2005.07.114_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1341-8076.2003.00087.x","article-title":"A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum","volume":"29","author":"Sehouli","year":"2003","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.ygyno.2005.07.114_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0169-5002(02)00502-0","article-title":"A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer","volume":"39","author":"Joppert","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ygyno.2005.07.114_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1081\/CNV-120022363","article-title":"Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer","volume":"21","author":"Dabrow","year":"2003","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ygyno.2005.07.114_bib23","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0090-8258(03)00470-0","article-title":"Weekly topotecan in the management of ovarian cancer","volume":"90","author":"Morris","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2005.07.114_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1016214032272","article-title":"A report on serious pulmonary toxicity associated with gemcitabine-based therapy","volume":"20","author":"Roychowdhury","year":"2002","journal-title":"Invest. New Drugs"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805006773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825805006773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T15:29:37Z","timestamp":1553095777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825805006773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0090825805006773"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2005.07.114","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}